Agendia – decoding cancer

Agendia is a leading molecular diagnostics company developing FFPE-based genomic diagnostic products, allowing clinically relevant gene expression profiling for cancer patients.

Agendia – decoding cancer


Agendia is a biotech company specialized in molecular diagnostics using DNA microarray technology for cancer diagnosis and drug development. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. This MammaPrint 70-gene Breast Cancer Recurrence Assay is the only breast cancer recurrence assay backed by peer-reviewed, prospective outcome data. Agendia’s tests are useful to assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, etc… Furthermore, RASTER (MicroarRAy PrognoSTics in Breast CancER) also confirmed the utility of the MammaPrint 70-gene signature to identify those breast cancer patients that may safely undertake chemotherapy. Additionally, ColoPrint 18-Gene Colon Cancer Recurrence Assay provides a definitive recurrence risk assessment for stage II colon cancer patients and eliminates the indeterminate results found in up to 70% of patients using traditional methods. Moreover, Agendia collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop a pipeline of other genomic products in the area of oncology (ISPY-2 and the MINDACT trials).

Agendia was founded in 2003 as a spin-off from the Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital in Amsterdam (Netherlands). Management Team is composed by Jan Egberts (CEO), Glen Fredenberg, Neil Barth, Guido Brink, Jeffrey Jones, Bastiaan van der Baan, Bob Brousseau, Annuska Glas, Laura van ‘t Veer, René Bernards and Peter Schineller. Board of Directors is composed by Hessel Lindenbergh, Colin Goddard, Pieter van der Meer, Harry Bartelink, Thomas Vanhoutte and Dharminder Chahal. MammaPrint is the fastest growing breast cancer recurrence assay, which already helped over 20.000 patients from over 34 countries.

More about Agendia :

Agendia – FFPE-based genomic diagnostic – gene expression profiling – decoding cancer – MammaPrint 70-gene Breast Cancer Recurrence Assay – ColoPrint 18-Gene Colon Cancer Recurrence Assay

Agendia – FFPE-based genomic diagnostics – FFPE based genomic diagnostic – DNA microarray – cancer diagnosis – breast cancer – MammaPrint 70 gene Breast Cancer Recurrence Assay – MammaPrint 70-gene Breast Cancer – MammaPrint – MammaPrint Breast Cancer – breast cancer recurrence assay – metastasis – RASTER – MicroarRAy PrognoSTics in Breast CancER – MammaPrint 70-gene – MammaPrint 70 gene – ColoPrint 18 Gene Colon Cancer Recurrence Assay – ISPY-2 – MINDACT – ISPY2 – Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital – Jan Egberts – Glen Fredenberg – Neil Barth – Guido Brink – Jeffrey Jones – Bastiaan van der Baan – Bob Brousseau – Annuska Glas – Laura van ‘t Veer – René Bernards – Peter Schineller – Hessel Lindenbergh – Colin Goddard – Pieter van der Meer – Harry Bartelink – Thomas Vanhoutte – Dharminder Chahal – Rene Bernards